skip to main content
Give

Fadi Khasawneh

Fadi Khasawneh
Fadi Khasawneh, PhD

Professor and Department Head of Pharmaceutical Sciences

Contact

Texas A&M Irma Lerma Rangel School of Pharmacy
1010 W. Ave. B
Kingsville, TX 78363
fkhasawneh@tamu.edu
Phone: 361.221.0755
Fax: 361.221.0793

Biography

Fadi Khasawneh, B.Pharm., Ph.D., is an Associate Professor and Department Head of Pharmaceutical Sciences, at the Texas A&M Irma Lerma Rangel College of Pharmacy. Dr. Khasawneh most recently served as the founding Chair of the Department of Pharmaceutical Sciences, at The University of Texas at El Paso’s School of Pharmacy. He had also served as a faculty member in the Department of Pharmaceutical Sciences at Western University of Health Sciences (Pomona, CA), College of Pharmacy.  Dr. Khasawneh received a bachelor’s degree in Pharmacy (B.Pharm) from Jordan University of Science and Technology (Irbid, Jordan) in 1999 and a Ph.D. in Pharmacology from the University of Illinois at Chicago (UIC) in 2007.

Dr. Khasawneh’s teaching interests are in the areas of pharmacology and principles of drug action. While at UTEP, he taught in the Principles of Drug Action, as well as in the Integrated Systems-Based Pharmacotherapy courses. He had also taught in the Pharmacological Basis of Therapeutics Courses at Western University of Health Sciences, as well as in their Master of Pharmaceutical Sciences program.

Dr. Khasawneh’s laboratory research is focused on the study of thrombosis and platelet biology. The primary goal is to delineate signaling pathways involved in platelet activation and to investigate their role in the pathogenesis of thrombotic diseases. They employ a host of molecular, biochemical and pharmacological approaches, as well as thrombosis models in their studies. Their ultimate goal is to identify novel therapeutic agents and/or targets for the management of thromboembolic disorders, such as heart attacks and stroke. His research program is currently funded by an R01 from the NIH’s NHLBI, an R21 from the NIEHS and a grant-in-aid from the American Heart Association (AHA).

Dr. Khasawneh is the chair elect for the Division of Cardiovascular Pharmacology, The American Society for Pharmacology and Experimental Therapeutics (ASPET), and had previously served as secretary/treasurer. He also served on ASPET’s programming and nominating committees. Dr. Khasawneh also served as Chair of the Biological Sciences section of the American Association of Colleges of Pharmacy (AACP). He served as Secretary of the Faculty Senate at The University of Texas at El Paso, and Chair of the Academic Senate at Western University of Health Sciences. He has served/is a reviewer for the NIH, Veterans Affairs, AACP, AHA, amongst others and is a reviewer for a host of scientific journals.

Education and Training

  • Academic Leadership Fellows Program (ALFP), American Association of Colleges of Pharmacy, Fellow of Cohort 14 , (2017-2018)
  • University of Illinois at Chicago, Chicago, IL, Ph.D., Pharmacology, 2007
  • Jordan University of Science & Technology, JORDAN, BS., Pharmacy (B.Pharm.), , 1999

Research Interests

  • Thirdhand Smoke Impact on Platelet Function and Thrombogenesis
  • The Role and Regulation of the Platelet Regulators of G-protein Signaling (RGS) Proteins
  • Drug Rediscovery/Repurposing
  • The Role and Regulation of the platelet Transient Potential Channel 6 (TRPC6)

Teaching Interests

  • Principles of Drug Action
  • Pharmacology
  • Research Methods

Awards, Recognition and Service

  • Chair, Division of Cardiovascular Pharmacology, The American Society for Pharmacology and Experimental Therapeutics, (2020-2022)
  • Chair, Hematology VA Merit Review Committee, Veterans Health Administration (2017-present)

Patents

  • Co-Inventor: Peptides and methods for inhibiting Galpha protein signaling. Status: Issued (No.: 8575103; Issue Date: 11/05/2013).

Representative Publications

Alarabi A.B., Karim Z.A., Ramirez, J.E.M., Hernandez, K.R., Lozano, P.A., Rivera J.O., Alshbool F.Z., and Khasawneh F.T., ”Short-Term Exposure to Waterpipe Smoke Triggers a Hyperactive Platelet Activation State and Increases the Risk of Thrombogenesis”, Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):335-349. 

Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. Ortiz-Munoz G, Yu MA, Lefrançais E, Mallavia B, Valet C, Tian JJ, Ranucci S, Wang KM, Liu Z, Kwaan N, Dawson D, Kleinhenz ME, Khasawneh FT, Haggie PM, Verkman AS, Looney MR. J Clin Invest. 2020 Jan 21. pii: 129635. 

Espinosa E.V.P., Lin O.A., Karim Z.A., Alshbool F.Z., and Khasawneh F.T., “Mouse Transient Receptor Potential Channel Type 6 Selectively Regulates Agonist-Induced Platelet Function”, Biochem Biophys Rep. 2019 Aug 31;20:100685. 

Hernandez, K.R., Karim Z.A., Qasim H., Druey K.M., Alshbool F.Z., and Khasawneh F.T., “The Regulator of G-Protein Signaling 16 is a Negative Modulator of Platelet Function and Thrombosis”, J Am Heart Assoc. 2019 Mar 5;8(5):e011273. 

Zhu Y., Romero E.L., Ren X., Du C., Liu C., Karim Z.A., Alshbool F.Z., Khasawneh F.T., Zhou J., Zhong D., and Geng B., “Enabling H2S Biomedicine: Clopidogrel as a Clinical Donor Probe and Thioenol Derivatives as Flexible Promoieties”, Nat Commun. 2018 Sep 27;9(1):3952.